CLAIMS
1. An EGF(A) derivative comprising an EGF(A) peptide analogue of the EGF(A) domain of LDL-R defined by SEQ ID NO 1, comprising 301 Leu and a substituent comprising at least one fatty acid group.
2. The EGF(A) derivative according to claim 1, wherein said substituent comprises a carboxylic acid, a sulphonic acid , a tetrazole moiety, a methylsulfonylcarbamoylamino moiety or a 3-hydroxy-isoxazole moiety and 8-20 consecutive -CH2- groups.
3. The EGF(A) derivative according to claim 1, wherein said substituent has Formula I: Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z1o- [I] wherein
Z1 is selected from:
Chem. 1: HOOC-(CH2)n-CO-*,
Chem. 2: tetrazolyl-(CH2)n-CO-*,
Chem. 3: HOOC-(C6H4)-0-(CH2)m-CO-*,
Chem. 4: HOS(0)2-(CH2)n-CO-*,
Chem. 5: MeS(0)2NH(CO)N-(CH2)n-CO-* and
Chem. 6: 3-HO-lsoxazole-(CH2)n-CO-*
wherein
n is an integer in the range of 8-20,
m is an integer in the range of 8-11,
the -COOH group in Chem. 3 can be attached to position 2, 3 or 4 on the phenyl
ring, the symbol * indicates the attachment point to the nitrogen in Z2 or, if Z2 is a
bond, to the nitrogen on the neighbouring Z element; Z2 is selected from
Chem. 7: *-NH-S02-(CH2)3-CO-*,
Chem. 8: *-NH-CH2-(C6H10)-CO-* and
a bond; Z3 is selected from:
yGlu, Glu and a bond; Z4, Z5, Z6, Z7, Z8, Z9 are selected, independently of each other, from:
Glu, yGlu, Gly, Ser, Ala, Thr, Ado, Aeep, Aeeep, TtdSuc and a bond; Z-io is selected from:
Chem. 14: *-NH-CH2-(C6H4)-CH2-* and a bond.

4. The EGF(A) derivative according to any of the previous claims, wherein the EGF(A)
derivative comprises one or two substituent(s) selected from the group consisting of:
HOOC-(CH2)i8-CO-gGlu-2xADO-
HOOC-(CH2)i8-CO-NH-CH2-(C6Hio)-CO-gGlu-2xADO-
HOOC-(CH2)i6-CO-gGlu-2xADO-
HOOC-(CH2)16-CO-gGlu-2xADO-NH-CH2-(C6H4)-CH2-
HOOC-(CH2)i6-CO-gGlu-
HOOC-(CH2)16-CO-NH-CH2-(C6H10)-CO-gGlu-2xADO-
HOOC-(CH2)i4-CO-gGlu-2xADO-
HOOC-(CH2)i4-CO-gGlu-
HOOC-(CH2)14-CO-gGlu-2xADO-
HOOC-(CH2)12-CO-gGlu-2xADO-
4-HOOC-(C6H4)-O-(CH2)10-CO-gGlu-2xADO-
4-HOOC-(C6H4)-O-(CH2)10-CO-gGlu-3xADO-
4-HOOC-(C6H4)-O-(CH2)10-CO-gGlu-
4-HOOC-(C6H4)-O-(CH2)10-CO-2xgGlu-
4-HOOC-(C6H4)-O-(CH2)10-CO-gGlu-3xGly-
4-HOOC-(C6H4)-O-(CH2)10-CO-2xgGlu-2xADO-
4-HOOC-(C6H4)-O-(CH2)10-CO-gGlu-TtdSuc-
4-HOOC-(C6H4)-0-(CH2)9-CO-
4-HOOC-(C6H4)-O-(CH2)10-CO-gGlu-4xADO-
4-HOOC-(C6H4)-0-(CH2)io-CO-NH-CH2-(C6Hio)-CO-gGlu-2xADO-
4-HOOC-(C6H4)-0-(CH2)9-CO-gGlu-2xADO-
3-HOOC-(C6H4)-0-(CH2)9-CO-gGlu-2xADO-
3-HO-lsoxazole-(CH2)12-CO-gGlu-2xADO-
HOS(0)2-(CH2)15-CO-gGlu-2xADO-NH-CH2-(C6H4)-CH2_
HOS(0)2-(CH2)i3-CO-gGlu-2xADO-
Tetrazolyl-(CH2)15-CO-NH-S02-(CH2)3-CO-ADO-ADO-NH-CH2-(C6H4)-CH2_
Tetrazolyl-(CH2)12-CO-gGlu-2xADO-
Tetrazolyl-(CH2)15-CO-gGlu-2xADO-and
MeS(0)2NH(CO)NH-(CH2)12-CO-gGlu-2xADO-.
5. The EGF(A) derivative according to any of the previous claims, wherein the EGF(A) peptide analogue comprises one, two, three, four or all five of the following (wild type) amino acid residue(s): 295Asn, 296Glu, 298Leu, 302Gly and 310Asp.
6. The EGF(A) derivative according to any of the previous claims, wherein the EGF(A) peptide analogue comprises the wild-type residue 310Asp.

7. The EGF(A) derivative according to any of the previous claims, wherein the EGF(A) peptide analogue comprises the wild-type residue 295Asn.
8. The EGF(A) derivative according to any of the previous claims wherein at least one substituent is attached to a Lys residue in the EGF(A) peptide analogue selected from the group consisting of: 292Lys, 293Lys, 294Lys, 296Lys, 299Lys, 300l_ys, 303l_ys, 305l_ys, 306l_ys, 309l_ys, 311 Lys, 312Lys, 313Lys, 314Lys, 315Lys, 316Lys, 318Lys, 320Lys, 321 Lys, 322Lys, 323Lys, 324Lys, 325Lys, 326Lys, 327Lys, 328Lys, 329Lys, 330Lys, 332Lys and 333Lys.
9. The EGF(A) derivative according to claim 1, wherein the EGF(A) derivative is selected from the group of EGF(A) derivatives consisting of: Example compounds 1-44, 46-47, 51-55, 57, 60-64, 66-69, 71-102 and 106-159.
10. An EGF(A) peptide analogue of the EGF(A) domain of LDL-R defined by SEQ ID NO 1, wherein the EGF(A) peptide analogue comprises 301 Leu, 310Asp and an amino acid substitution of 312Lys.
11. An EGF(A) peptide analogue of the EGF(A) domain defined by SEQ ID NO 1, wherein the EGF(A) peptide analogue comprises 301 Leu and 310Asp and wherein the peptide does not have a substitution of 299Asp to Glu, Val or His.
12. The EGF(A) peptide analogue according to claim 10 or 11, wherein the EGF(A) peptide analogue comprises Cys residues 297Cys, 304Cys, 308Cys, 317Cys, 319Cys and
331 Cys.
13. The EGF(A) peptide analogue according any of the previous claims 10 - 12, further comprising one, two, three, four or all five of the following (wild type) amino acid residue(s): 295Asn, 296Glu, 298Leu, 302Gly and 310Asp.
14. The EGF(A) peptide analogue according any of the previous claims 10- 12, EGF(A) further comprising at least one Lys substitution selected from the group consisting of: 292Lys, 293Lys, 294Lys, 296Lys, 299Lys, 300Lys, 303Lys, 305Lys, 306Lys, 309Lys, 311 Lys, 313Lys, 314Lys, 315Lys, 316Lys, 318Lys, 320Lys, 321 Lys, 322Lys, 323Lys, 324Lys, 325Lys, 326Lys, 327Lys, 328Lys, 329Lys, 330Lys, 332Lys and 333Lys.

15. The EGF(A) peptide analogue according to any of the previous claims 10-12, wherein said peptide sequence is selected from the group consisting of: SEQ ID NO.: 2-47 and 49-106.